Sanofi - American Depositary Shares (NQ:SNY)

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗

January 05, 2026

Via MarketBeat

Topics Artificial Intelligence Death

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗

Topics Economy Intellectual Property

December 31, 2025

Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

Topics Economy Government

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a...

Topics ETFs Intellectual Property

The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit

December 26, 2025

The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies

December 25, 2025

Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been...

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Topics Economy Intellectual Property

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

A healthcare titan wants to buy the biotech's vaccines.

Topics Artificial Intelligence Economy Intellectual Property

Why Dynavax Stock Soared Today ↗

December 24, 2025

Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine

December 24, 2025

As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the...

Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax...

Topics Artificial Intelligence Economy Intellectual Property

Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition

December 24, 2025

In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge...

Topics Economy

Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring

December 24, 2025

French drugmaker Sanofi agreed to acquire vaccine maker Dynavax in a $2.2 billion deal.

Topics Intellectual Property

Why Did Dynavax Stock Surge 38% In Premarket Today? ↗

December 24, 2025

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

December 23, 2025

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Topics Government

December 23, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

Topics ETFs Economy Intellectual Property

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

This hot biotech stock could have a lot more room to run.

Topics Government World Trade

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

Moderna tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.

Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗

December 01, 2025

The comeback may have begun.

Topics Death

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗

November 30, 2025

Sanofi stock dropped Wednesday after French authorities raided the firm's headquarters as part of a tax fraud investigation.

Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation ↗

November 26, 2025

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Topics Fraud

November 25, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines

November 14, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This...

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

Topics Artificial Intelligence Economy Product Recall

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Roche is great at developing drugs -- but is its stock a great buy?

Topics Artificial Intelligence Economy Intellectual Property

Why Roche Holding Stock Popped Today ↗

November 10, 2025

Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗

November 10, 2025

Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%.

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗

November 08, 2025

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

Topics Artificial Intelligence Intellectual Property

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...

Topics Artificial Intelligence

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025